A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers.

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2015

At a glance

  • Drugs Fluorouracil; Folinic acid; Oxaliplatin; Tivozanib
  • Indications Colorectal cancer; Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 22 Jan 2011 Results from this trial presented at the ASCO Gastrointestinal Cancers Symposium in January 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top